Skip to main content

Table 4 Association of PD with participants’ clinical characteristics

From: Prevalence and factors associated with psychological distress among patients on warfarin at the Uganda Heart Institute, Mulago Hospital

 

PD present n = 63 (32%)

PD absent n = 134 (68%)

OR (95% CI)

P value

Underlying CVD diagnosis

 Rheumatic heart disease

22 (22.5)

76 (77.6)

1

 

 Atrial fibrillation

22 (41.5)

31 (58.5)

2.45 (1.19–5.06)

0.02

 Thrombo-embolism

9 (30.0)

21 (70.0)

1.48 (0.59–3.69)

0.40

Length of time on Warfarin

  ≤ 6 months

17 (43.6)

22 (56.4)

1

 

 7–24 months

12 (21.1)

45 (78.9)

0.35 (0.14–0.85)

0.02

 25–60

15 (26.8)

41 (73.2)

0.47 (0.20–1.13)

0.09

  > 60

13 (37.1)

22 (62.9)

0.76 (0.30–1.94)

0.57

Other comorbidities

 No comorbidity

44 (27.3)

117 (72.7)

1

 

 Any comorbidity

19 (52.8)

17 (47.2)

2.97 (1.42–6.23)

< 0.01

History of cardiac surgey

 No

40 (29.0)

98 (71.0)

1

 

 Yes

22 (37.9)

36 (62.1)

1.50 (0.79–2.85)

0.22

Length from time of surgery

  < 1 year

4 (33.3)

8 (66.7)

1

 

 1 to < 3 years

9 (40.9)

13 (59.1)

1.38 (0.32–6.03)

0.67

 3 to 5 years

4 (40.0)

6 (60.0)

1.33 (0.23–7.63)

0.75

  > 5 years

5 (38.5)

8 (61.5)

1.25 (0.24–6.44)

0.79

Chronic medication beside Warfarin

 Loop diuretic

  No

20 (21.7)

72 (78.3)

1

 

  Yes

43 (41.0)

62 (59.0)

2.50 (1.33–4.69)

< 0.01

 Penicillin

  No

71 (63.4)

41 (36.6)

  

  Yes

22 (25.9)

63 (74.1)

0.60 (0.33–1.12)

0.11

 Beta blocker

  No

83 (70.3)

35 (29.7)

1

 

  Yes

28 (35.4)

51 (64.6)

1.30 (0.71–2.39)

0.39

 Cardiac glycoside

  No

41 (29.7)

97 (70.3)

1

 

  Yes

22 (37.3)

37 (62.7)

1.40 (0.74–2.67)

0.30